Citizens JMP reiterates Market Perform rating on Globus Medical stock

Globus Medical (GMED) reported robust Q2 2025 results, with adjusted EPS of $0.86 significantly surpassing Street expectations and sales slightly exceeding forecasts, driven by a notable operational recovery from prior supply chain challenges. The medical device manufacturer achieved a new quarterly record for adjusted EPS and demonstrated strong profitability with a 67.1% gross margin and healthy liquidity. Despite this strong performance and a subsequent after-hours stock increase, the company maintained its full-year guidance, suggesting a cautious outlook.

Analysis

Globus Medical (GMED) delivered a robust second-quarter 2025 performance, highlighted by significant operational recovery and financial results that surpassed market expectations. The company posted a record adjusted earnings per share of $0.86, outperforming consensus estimates of $0.75 by approximately 15%, while revenue of $745.3 million also slightly beat forecasts with 3% year-over-year growth. This financial outperformance was driven by the resolution of prior operational challenges, with management noting that product supply has "dramatically improved." This is substantiated by a nearly 60% sequential rebound in Enabling Technologies revenue and 6% year-over-year growth in the U.S. Spine segment. The company's fundamental health appears strong, supported by an impressive 67.1% gross margin and a healthy current ratio of 4.07. However, a key point of consideration is that despite the strong quarterly beat and a subsequent increase in after-hours trading, Globus Medical maintained its full-year guidance for both revenue and EPS, which may suggest management conservatism or that future quarters might not sustain this level of outperformance. This cautious outlook is mirrored by the reiterated 'Market Perform' rating from Citizens JMP.

Key Decisions for Investors

• Given the strong Q2 earnings beat and operational turnaround, investors could see the current valuation as attractive, especially as after-hours trading showed positive momentum.
• It is crucial to weigh the record quarterly EPS against the company's decision to maintain full-year guidance, which could signal that the positive performance may not accelerate through the rest of the year.
• Consider monitoring management's future commentary for insights into their conservative guidance, as the reiterated 'Market Perform' rating suggests some analysts believe the stock is appropriately valued despite the strong quarter.